Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
8 Results for "
nuclear envelope
" in MedChemExpress (MCE) Product Catalog:
Products (8)
8 Results for "nuclear envelope" in MCE Product Catalog:
Cat. No.: HY-E70653
CDK1 is a cyclin-dependent kinase that functions as a serine/threonine protein kinase, and is a key player in cell cycle regulation. CDK1/CycB1 Recombinant Human Active Protein Kinase is an ortholog of CDK1. CDK1/cyclin B1 complexes initiates mitotic entry by phosphorylating a multitude of proteins to condense chromosomes, disrupt the nuclear envelope, and enable microtubules polymerization to attach and to segregate the chromosomes .
Cat. No.: HY-159150
CAS No.: 2762922-66-5
HIV-1 inhibitor-71 (compound 2a) blocks the transport of endocytosed HIV-1 particles into nuclear envelope invagination (NEIs) that can inhibit productive infection .
Cat. No.: HY-184293
PROTAC ATR degrader-4 is a PROTAC-based ATR kinase degrader, with a DC50 of 6.18 μM and a Dmax of 71.42% in LoVo cells. PROTAC ATR degrader-4 downregulates ATR protein expression, inducing nuclear envelope rupture, genomic instability, DNA damage and apoptosis. PROTAC ATR degrader-4 exhibits anti-tumor activity in xenograft tumor mouse models and can be used for the research of atm-deficient cancers .
Cat. No.: HY-P72263
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: NUP210; nuclear Pore Membrane Glycoprotein 210; Nucleoporin 210; Pore Membrane Protein Of 210 KDa; POM210; nuclear Pore Protein Gp210; KIAA0906; Nucleoporin 210kDa; GP210; Nucleoporin Nup210; nuclear envelope Pore Membrane Protein POM 210; FLJ22389
Species:
Human
Source:
E. coli
Cat. No.: HY-P77109
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: NUP210; nuclear Pore Membrane Glycoprotein 210; Nucleoporin 210; Pore Membrane Protein Of 210 KDa; POM210; nuclear Pore Protein Gp210; KIAA0906; Nucleoporin 210kDa; GP210; Nucleoporin Nup210; nuclear envelope Pore Membrane Protein POM 210; FLJ22389
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-P810459
Synonyms: SYNE3, Spectrin Repeat Containing nuclear envelope Family Member 3, Nesprin-3, LINC00341, NET53, Long Intergenic Non-Protein Coding RNA 341, nuclear envelope Spectrin Repeat Protein 3, KASH Domain-Containing Protein 3, NCRNA00341, C14orf139, FLJ25605, C14orf49, Nesp3, KASH3, Chromosome 14 Open Reading Frame 139, Chromosome 14 Open Reading Frame 49, Uncharacterized Protein C14orf113, Non-Protein Coding RNA 341, C14ORF139, NESPRIN-3, C14ORF49, NESP3
Cat. No.: HY-187035
CAS No.: 868066-26-6
SNX631 is an orally active and selective CDK8/CDK19 inhibitor. SNX631 reduces the phosphorylation of STAT1/STAT3 S727, and upregulates miR-21-5p, miR-21-3p and miR-221 in cancer cells. SNX631 transcription-independently inhibits meiotic resumption in mouse oocytes, blocks nuclear envelope breakdown, first polar body extrusion and mitochondrial expansion and aggregation, with no cytotoxicity. SNX631, in combination with Lapatinib (HY-50898) or Trastuzumab (HY-P9907), synergistically inhibits cancer cell growth, upregulates the tumor suppressor BTG2, prevents Lapatinib-induced upregulation of oncogenic miRNAs, overcomes drug resistance, reduces the infiltration of αSMA+ stromal fibroblasts and ARG1+ M2 macrophages, and exhibits favorable biosafety. SNX631 can be used in studies related to HER2-positive breast cancer and cancer .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
